Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
11
02
2018
accepted:
09
08
2018
pubmed:
28
9
2018
medline:
4
6
2020
entrez:
28
9
2018
Statut:
ppublish
Résumé
Little has been published about the association of venous thromboembolism (VTE) and sarcoma. In this study, we sought to identify clinical features of patients with sarcoma presenting at least one VTE episode. Our study was a retrospective case-control study of a single-institution database with univariate and multivariate analysis using chi-square and Student's The overall incidence of VTE in patients with sarcoma was 7.9%. Predictive factors identified by multivariate analysis were metastatic disease and administration of chemotherapy. It was not statistically possible to correlate the risk of VTE with specific sarcoma subtypes, but observations suggested malignant peripheral nerve sheath tumor, osteosarcoma, and liposarcoma as having the highest propension. VTE is not infrequent in patients with sarcoma. Adoption of common guidelines for cancer-associated thrombosis is recommended.
Sections du résumé
BACKGROUND
Little has been published about the association of venous thromboembolism (VTE) and sarcoma. In this study, we sought to identify clinical features of patients with sarcoma presenting at least one VTE episode.
METHODS
Our study was a retrospective case-control study of a single-institution database with univariate and multivariate analysis using chi-square and Student's
RESULTS
The overall incidence of VTE in patients with sarcoma was 7.9%. Predictive factors identified by multivariate analysis were metastatic disease and administration of chemotherapy. It was not statistically possible to correlate the risk of VTE with specific sarcoma subtypes, but observations suggested malignant peripheral nerve sheath tumor, osteosarcoma, and liposarcoma as having the highest propension.
CONCLUSION
VTE is not infrequent in patients with sarcoma. Adoption of common guidelines for cancer-associated thrombosis is recommended.
Identifiants
pubmed: 30257890
pii: theoncologist.2018-0081
doi: 10.1634/theoncologist.2018-0081
pmc: PMC6519765
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e111-e114Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Thromb Res. 2017 Oct;158:157-160
pubmed: 28926801
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
J Thromb Haemost. 2017 Aug;15(8):1567-1575
pubmed: 28585779
N Engl J Med. 2012 Feb 16;366(7):601-9
pubmed: 22335737
J Surg Oncol. 2011 Jun 1;103(7):643-7
pubmed: 21370234
Eur J Cancer. 2012 Jun;48(9):1283-92
pubmed: 22100906
Oncologist. 2017 Feb;22(2):199-207
pubmed: 28174293
Thromb Haemost. 2017 Jan 5;117(1):57-65
pubmed: 27709226
J Clin Oncol. 2015 Feb 20;33(6):654-6
pubmed: 25605844
Surg Oncol Clin N Am. 2016 Oct;25(4):621-43
pubmed: 27591490
Thromb Res. 2010 Apr;125 Suppl 2:S1-7
pubmed: 20433985
Haematologica. 2017 Sep;102(9):1494-1501
pubmed: 28550192
Clin Sarcoma Res. 2015 Jul 26;5:18
pubmed: 26213607